Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516746 · ClinicalTrials.gov registry record · Phase 3
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
A Phase 3 study of COVID-19 and SARS-CoV-2, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 32,450
- Enrollment target
- 20
- Study locations
NCT04516746 is a Phase 3 study of COVID-19 and SARS-CoV-2 that has completed, run by AstraZeneca. The registered enrollment target is 32,450 participants, below the 55,055-participant average among 203 other COVID-19 trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04516746, a Phase 3 study of COVID-19 and SARS-CoV-2, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32,450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AZD1222
Study Locations (20)
California
- Research Site - Berkeley
- Research Site - El Centro
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - San Diego
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - San Francisco
- Research Site - Torrance
Florida
- Research Site - Coral Gables
- Research Site - Lake Worth
- Research Site - Miami Lakes
- Research Site - Orlando
Arizona
- Research Site - Phoenix
- Research Site - Scottsdale
Arkansas
- Research Site - Little Rock
Colorado
- Research Site - Denver
Connecticut
- Research Site - Danbury
Hawaii
- Research Site - Honolulu
Idaho
- Research Site - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32,450 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04516746
The ClinicalTrials.gov registry entry for NCT04516746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32,450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,055-participant average among 203 other COVID-19 trials with a reported enrollment target (41% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04516746 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04516746 about?
NCT04516746 is a clinical study titled "Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults". The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
What is the current status of trial NCT04516746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32,450 participants. The study started on 2020-08-28. Estimated completion is 2023-02-10.
What conditions does trial NCT04516746 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
What interventions are being tested in trial NCT04516746?
The interventions under investigation include: Placebo (BIOLOGICAL), AZD1222 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04516746?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04516746 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.